J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
source https://finance.yahoo.com/news/j-js-prostate-cancer-drug-153203664.html?.tsrc=rss
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
source https://finance.yahoo.com/news/j-js-prostate-cancer-drug-153203664.html?.tsrc=rss
blaineonline.finance.blog 